Weather Related Conditions Cancels Alimera Sciences Presentation at Rodman & Renshaw Global Investment Conference
September 11 2017 - 4:01PM
Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in
commercialization and development of prescription ophthalmic
pharmaceuticals, announced that due to the severe tropical
storm impacting the southeast, it has canceled it’s previously
announced presentation and webcast at the Rodman & Renshaw
Global Investment Conference in New York City which was scheduled
for September 12, at 3:00 PM ET.
About Alimera Sciences,
Inc.Alimera, founded in June 2003, is a pharmaceutical
company that specializes in the commercialization and development
of prescription ophthalmic pharmaceuticals. Alimera is presently
focused on diseases affecting the back of the eye, or retina,
because these diseases are not well treated with current therapies
and will affect millions of people in aging populations. Alimera's
commitment to retina specialists and their patients is manifest in
its product and in its development portfolio designed to treat
early- and late-stage diseases. For more information, please visit
www.alimerasciences.com.
Forward-Looking StatementsThis
press release contains "forward-looking statements," within the
meaning of the Private Securities Litigation Reform Act of 1995,
regarding, among other things, the opportunity for further growth
in 2017 for ILUVIEN and the ability of Alimera to achieve positive
operating cash flow. Such forward-looking statements are based on
current expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change any of them,
and could cause actual results to differ materially from those
projected in its forward-looking statements. Meaningful factors
which could cause actual results to differ include, but are not
limited to, continued market acceptance of ILUVIEN in the U.S. and
Europe, including physicians' ability to obtain reimbursement, as
well as other factors discussed in the "Risk Factors" and
"Management's Discussion and Analysis of Financial Condition and
Results of Operations" sections of Alimera's Annual Report on Form
10-K for the year ended December 31, 2016 and Quarterly Report on
Form 10-Q for the quarter ended March 31, 2017, which are on file
with the Securities and Exchange Commission (the SEC) and available
on the SEC's website at http://www.sec.gov. Additional factors may
be set forth in those sections of Alimera's Quarterly Report on
Form 10-Q for the quarter ended June 30, 2017, to be filed with the
SEC in the third quarter of 2017. In addition to the risks
described above and in Alimera's Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and
other filings with the SEC, other unknown or unpredictable factors
also could affect Alimera's results. There can be no assurance that
the actual results or developments anticipated by Alimera will be
realized or, even if substantially realized, that they will have
the expected consequences to, or effects on, Alimera. Therefore, no
assurance can be given that the outcomes stated in such
forward-looking statements and estimates will be achieved. All
forward-looking statements contained in this press release are
expressly qualified by the cautionary statements contained or
referred to herein. Alimera cautions investors not to rely too
heavily on the forward-looking statements Alimera makes or that are
made on its behalf. These forward-looking statements speak only as
of the date of this press release (unless another date is
indicated). Alimera undertakes no obligation, and specifically
declines any obligation, to publicly update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise.
For investor inquiries:CG
Capitalfor Alimera
Sciences877-889-1972investorrelations@cg.capital
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Sep 2023 to Sep 2024